
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
August 22, 2023
Principal Technologies (TSXV:PTEC) focuses on investing in life-saving and life-improving healthcare technologies and innovations. The company intends to invest in private healthcare technology companies in Europe and bring them to the North American marketplace to benefit from the region's higher valuation of med-tech companies.
The company has a highly experienced leadership team including Jerry Trent, a highly accomplished international investment banker and portfolio manager; Prince Alfred of Liechtenstein, a senior member of the Liechtenstein family; Dr. Gerald Rainer, former CEO of Switzerland’s largest and most prestigious asset management company; and Dr. Ivo Ivanovski, former European IT Minister and currently CEO of Telekom Austria Group’s Tower Co.

Principal increases shareholder value by steadily growing the company’s financial performance, and paying off debt with improved cash flows and new equity when capital markets are advantageous.
Over the next 12 months, the company plans to acquire a private healthcare technology company, which will substantially transform its operations and provide it with a platform for growth.
Company Highlights
- Principal Technologies is a healthcare technologies investor targeting leading and proven European healthcare technologies.
- Principal drives value in its investments by purchasing them at a discount in the EU and exposing them to the North American market, which offers significantly higher valuations for healthcare technology companies.
- The company is managed, directed and advised by a group of incredibly experienced entrepreneurs and investors, all of whom maintain close industry connections in the EU.
- When acquiring a new target, Principal's first step is to ensure an equity control position. It will typically finance the acquisition through a combination of debt and equity, accessing major EU funds when financing leveraged buyouts.
- Principal has implemented multiple checks, balances and strategies to reduce and manage risk, including:
- Maintaining profit-oriented compensation plans to incentivize performance.
- Maintaining strict capital allocation at the corporate level.
- Ensuring a margin of safety compared to intrinsic value in negotiating its acquisition prices.
- Principal exclusively seeks managers and advisors who will allow it to broaden its competitive advantage, expand its operations and support international expansion.
This Principal Technologies profile is part of a paid investor education campaign.*
Click here to connect with Principal Technologies (TSXV:PTEC) to receive an Investor Presentation
PTEC:CC
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
The Conversation (0)
20 February 2024
Principal Technologies
Building an Investment Portfolio of Disruptive Healthcare Technology Companies
Building an Investment Portfolio of Disruptive Healthcare Technology Companies Keep Reading...
08 September
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)BriaCell Phase 3 trial featured in Nature Medicine as "Eleven clinical trials that will shape medicine in 2026" briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage... Keep Reading...
24 August
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+
Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
20 August
Moderna, Merck Shares Soar on Cancer Vaccine Trial Success
An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
11 August
Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
05 August
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
04 August
Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status
The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00



